:
The mechanisms governing the development and progression of cancers are
believed to be the consequence of hereditary deformities and epigenetic modifications.
Accordingly, epigenetics has become an incredible and progressively explored field of
research to discover better prevention and therapy for neoplasia, especially triple-negative
breast cancer (TNBC). It represents 15–20% of all invasive breast cancers and will, in
general, have bellicose histological highlights and poor clinical outcomes. In the early
phases of triple-negative breast carcinogenesis, epigenetic deregulation modifies
chromatin structure and influences the plasticity of cells. It up-keeps the oncogenic
reprogramming of malignant progenitor cells with the acquisition of unrestrained selfrenewal capacities. Genomic impulsiveness in TNBC prompts mutations, copy number
variations, as well as genetic rearrangements, while epigenetic remodeling includes an
amendment by DNA methylation, histone modification, and noncoding RNAs of gene
expression profiles. It is currently evident that epigenetic mechanisms assume a
significant part in the pathogenesis, maintenance, and therapeutic resistance of TNBC.
Although TNBC is a heterogeneous malaise that is perplexing to describe and treat, the
ongoing explosion of genetic and epigenetic research will help to expand these
endeavors. Latest developments in transcriptome analysis have reformed our
understanding of human diseases, including TNBC at the molecular medicine level. It is
appealing to envision transcriptomic biomarkers to comprehend tumor behavior more
readily regarding its cellular microenvironment. Understanding these essential biomarkers
and molecular changes will propel our capability to treat TNBC adequately. This review
will depict the different aspects of epigenetics and the landscape of transcriptomics in
triple-negative breast carcinogenesis and their impending application for diagnosis,
prognosis, and treatment decision with the view of molecular medicine.